Open Access
Copyright: The authors. This article is an open access
article licensed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0) which permits unrestricted use,
distribution and reproduction in any medium, provided the work is properly
cited.
Review Article
15.
Bispecific antibodies and their use in applied
research -
Harshit Verma, Durairajan Ramachandran, Ashabaree
Samal
Vet World. 2012; 5(12): 775-780
doi:
10.5455/vetworld.2012.7
75-780
Abstract
Bispecific antibodies (BsAb) can, by virtue of
combining two binding specificities, improve the
selectivity and efficacy of antibody-based treatment
of human disease. Antibodies with two distinct
binding specificities have great potential for a
wide range of clinical applications as targeting
agents for in vitro and in vivo immunodiagnosis,
therapy and for improving immunoassays. They have
shown great promise for targeting cytotoxic effector
cells, delivering radionuclides, toxins or cytotoxic
drugs to specific targets, particularly tumour
cells. The development of BsAb research goes through
three main stages: chemical cross linking of murine-derived
monoclonal antibody, hybrid hybridomas and
engineered BsAb. This article is providing the
potential applications of bispecific antibodies.
Keywords: bispecific antibodies, immunoassay,
immunotherapy, monoclonal antibody
